Research location
Maroochydore
Australia
Advertisement
Research activity in Maroochydore
AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 20 trials and 20 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Maroochydore
20 linked trials · page 1 of 1A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · 2026-02-10 · 1 site observation
RECRUITING
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 · 2025-10-16 · 1 site observation
RECRUITING
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538 · 2024-12-04 · 1 site observation
RECRUITING
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18 · 1 site observation
COMPLETED
A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06595238 · 2024-10-01 · 1 site observation
COMPLETED
A Study of LY3337641 in Rheumatoid ArthritisNCT02628028 · 2016-08-22 · 1 site observation
TERMINATED
A Crossover Study of the Safety and Tolerability of Two Formulations of AdalimumabNCT01502423 · 2012-01-01 · 1 site observation
COMPLETED
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid ArthritisNCT01194414 · 2010-09-01 · 1 site observation
COMPLETED
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)NCT01146652 · 2010-06-21 · 1 site observation
COMPLETED
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid ArthritisNCT01119859 · 2010-05-01 · 1 site observation
COMPLETED
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis PatientsNCT01061736 · 2010-03-01 · 1 site observation
COMPLETED
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyNCT00973479 · 2009-09-01 · 1 site observation
COMPLETED
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.NCT00448591 · 2006-09-01 · 1 site observation
COMPLETED
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00361335 · 2006-09-01 · 1 site observation
COMPLETED
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naiveNCT00264537 · 2005-12-01 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00264550 · 2005-12-01 · 1 site observation
COMPLETED
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid ArthritisNCT00721123 · 2005-08-01 · 1 site observation
COMPLETED
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisNCT00175877 · 2005-06-01 · 1 site observation
COMPLETED
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid ArthritisNCT00195663 · 2000-12-01 · 1 site observation
COMPLETED
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid ArthritisNCT00106548 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.